First-in-human (FIH) trial evaluating immune activation and safety of PIN-2 administered intravenously to patients with advanced solid tumors.

被引：0
作者：
Bier, Colin
Millward, Michael
Kotasek, Dusan
Gorelick, Kenneth J.
Goldberg, Joshua Brian
机构：
[1] PIN Pharma Inc, New York, NY USA
[2] Sch Med & Pharmacol, Nedlands, WA, Australia
[3] Adelaide Canc Ctr, Kurralta Pk, Adelaide, SA, Australia
[4] Univ Adelaide, Kurralta Pk, Adelaide, SA, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.2600
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2600
引用
收藏
页数：1
相关论文
共 50 条
  • [31] First-in-human dose escalation study of oral ONC201 in advanced solid tumors.
    Stein, Mark N.
    Mayer, Tina M.
    Moss, Rebecca Anne
    Silk, Ann W.
    Chan, Nancy
    Haffty, Bruce George
    DiPaola, Robert S.
    Beckett, Yasmeen
    Bentlyewski, Edward
    Zheng, Ling
    Fang, Bruno
    Allen, Joshua
    Mehnert, Janice M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] A CRUK first-in-human phase I trial of LY3143921, a novel CDC7 inhibitor, in patients with advanced solid tumors.
    Gallagher, Peter F.
    Naylor, Gregory
    Bashir, Saira
    Yan, Xiangfei
    Burke, David
    Plummer, Elizabeth Ruth
    Evans, T. R. Jeffry
    Coyle, Victoria M.
    Clive, Sally
    McGuigan, Lesley
    Heinzmann, Kathrin
    Halbert, Gavin
    Veal, Gareth
    Tiplady, Eleanor
    Barnett, Shelby
    Yalla, Krishna
    Brook, Sue
    Dobbs, Nicola
    Wilson, Richard H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] A FIRST-IN-HUMAN PHASE 1/2 OPEN LABEL TRIAL EVALUATING THE SAFETY, PHARMACOLOGY, AND PRELIMINARY EFFICACY OF VT1021 IN SUBJECTS WITH ADVANCED SOLID TUMORS
    Mahalingam, Devalingam
    Harb, Wael
    Patnaik, Amita
    Ulahannan, Susanna
    Mahdi, Haider
    Ahluwalia, Manmeet
    Patel, Manish
    Dowlati, Afshin
    Bullock, Andrea
    Wen, Patrick
    Pant, Shubham
    Mulcahy, Mary
    Guttendorf, Robert
    Vaickus, Lou
    Wang, Suming
    Crochiere, Marsha
    Vincent, Melanie
    Cieslewicz, Michael
    Watnick, Jing
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A228 - A228
  • [34] A phase 1, first-in-human, dose-escalation and biomarker trial of liposomal gemcitabine (FF-10832) in patients with advanced solid tumors.
    Borazanci, Erkut Hasan
    Janku, Filip
    Hamilton, Erika P.
    Thomas, Jacob Stephen
    Sen, Shiraj
    Fu, Siqing
    Wheeler, Catherine A.
    Wages, David S.
    Matsumoto, Takeshi
    Shimoyama, Susumu
    Yamada, Naoki
    Subach, Ruth Ann
    Madden, Timothy
    Johansen, Mary
    Maier, Gary
    Cheung, Kin
    Korn, Ron
    Falchook, Gerald Steven
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] A first-in-human phase 1 dose-escalation trial of the oral HIF-2a inhibitor PT2977 in patients with advanced solid tumors.
    Papadopoulos, Kyriakos P.
    Jonasch, Eric
    Zojwalla, Naseem J.
    Wang, Keshi
    Bauer, Todd Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] A CRUK first-in-human phase I trial of a CDC7 Inhibitor, LY3143921 hydrate, in patients with advanced solid tumors.
    Gallagher, Peter F.
    Coyle, Victoria
    Evans, T. R. Jeffry
    Plummer, Elizabeth Ruth
    Clive, Sally
    McGuigan, Lesley
    Roxburgh, Patricia
    Haris, Noor Md
    Symeonides, Stefan N.
    Naylor, Gregory
    Bashir, Saira
    Stanley, Barbara
    Godfrey, Lisa
    Elliott, Moira
    Halbert, Gavin
    Brook, Sue
    Dobbs, Nicola
    Wilson, Richard H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] First-in-human study of TAS-115, a novel oral MET/VEGFR inhibitor, in patients with advanced solid tumors.
    Matsubara, Nobuaki
    Shitara, Kohei
    Naito, Yoichi
    Kuboki, Yasutoshi
    Ohno, Izumi
    Takahashi, Hideaki
    Bando, Hideaki
    Kojima, Takashi
    Fuse, Nozomu
    Yamazaki, Tomoko
    Hirayama, Naoki
    Fujita, Hidenori
    Nishida, Toshirou
    Doi, Toshihiko
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-1287 administered daily to patients with advanced solid tumors.
    Ben George
    Richards, Donald A.
    Edenfield, William Jeffory
    Warner, Steven L.
    Mouritsen, Lars
    Bishop, Reyna
    Anthony, Stephen Patrick
    Bearss, David
    Vogelzang, Nicholas J.
    Whatcott, Clifford
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] A first-in-human, phase 1 study evaluating oral TACC3 inhibitor, AO-252, in advanced solid tumors.
    Dumbrava, Ecaterina Elena
    Kennon, Amber Michelle
    Balema, Wintana A.
    Lim, Chaemin
    Vempati, Sridhar
    Stergiopoulos, Sotirios
    Richardson, Debra L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors.
    Mehra, Ranee
    Camidge, D. Ross
    Sharma, Sunil
    Felip, Enriqueta
    Tan, Daniel Shao-Weng
    Vansteenkiste, Johan F.
    De Pas, Tommaso Martino
    Kim, Dong-Wan
    Santoro, Armando
    Liu, Geoffrey
    Goldwasser, Meredith
    Dai, David
    Radona, Marietta
    Boral, Anthony
    Shaw, Alice Tsang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345